Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)

Authors not listed

Ionis Pharmaceuticals, Inc. · 2024

Abstract

The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2024). A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study). <em>Ionis Pharmaceuticals, Inc.</em>. https://clinicaltrials.gov/study/NCT06673069
Vancouver
Anonymous. A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study). Ionis Pharmaceuticals, Inc.. 2024.
BibTeX
@misc{anon2024APhase, title = {A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)}, author = {Anonymous}, journal = {Ionis Pharmaceuticals, Inc.}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings